Cellectis S.A. (CLLS) vs Nuvalent Inc (NUVL)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| CLLS | NUVL | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Size band | SMALL | MID |
| Listing | Nasdaq GM | Nasdaq GM |
| Country | France | United States |
| Theme | cell-therapy | oncology |
| Price and returns | ||
| Last close | $0.97 | $123.96 |
| Return · 1 week | +4.37% | 0.00% |
| Return · 1 month | −34.70% | 0.00% |
| Return · 3 months | −65.97% | 0.00% |
| Return · year to date | −79.86% | +22.93% |
| Return · 1 year | −73.37% | +26.87% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −82.27% | −0.02% |
| 52-week high | $5.45 | $123.99 |
| 52-week low | $0.88 | $87.30 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $97.36M | $9.79B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $39.87K | $149.69M |
| Employees | 224 | 234 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | n/a (negative earnings) |
| Price to earnings · forward | n/a (negative forward earnings) | n/a (negative forward earnings) |
| Price to sales | 1.99× | — |
| Price to book | 2.23× | 8.33× |
| Enterprise value to EBITDA | n/a (negative EBITDA) | — |
| Enterprise value to revenue | 0.17× | — |
| Earnings per share · trailing | -0.64 | -6.06 |
| Profitability | ||
| Gross margin | 82.27% | — |
| Operating margin | −340.69% | 0.00% |
| Profit margin | −102.34% | — |
| Return on equity | −94.54% | −41.19% |
| Return on assets | −11.67% | −22.51% |
| Growth | ||
| Revenue growth | −62.10% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 195.66 | — |
| Current ratio | 1.37 | 16.14 |
| Dividend yield | 0.00% | — |
| Payout ratio | 0.00% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 23.09 | — |
| ADX · 14 | 58.26 | — |
| 50-day average | $2.05 | — |
| 200-day average | $3.13 | — |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 9.62% | — |
The full CLLS analysis
Everything this table leaves out for Cellectis S.A.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the CLLS argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full CLLS analysisThe full NUVL analysis
Everything this table leaves out for Nuvalent Inc: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the NUVL argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full NUVL analysis